How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review

• Published in: Journal of clinical medicine Vol. 13; no. 7; p. 2119
• Main Authors: Parrini, Iris, Lucà, Fabiana, Rao, Carmelo Massimiliano, Cacciatore, Stefano, Riccio, Carmine, Grimaldi, Massimo, Gulizia, Michele Massimo, Oliva, Fabrizio, Andreotti, Felicita
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2024
• Subjects: Adrenergic beta blockers; Age; Aged patients; beta-blockers; clinical trial; Comorbidity; Demographic aspects; Dosage and administration; Drug therapy; Ejection fraction; Heart failure; HFpEF; HFrEF; Medical prognosis; Mortality; Older people; Patient outcomes; Polypharmacy; Therapy; ventricular dysfunction; United States; Europe; clinical trial; frailty; heart failure; aged; beta-blockers; multimorbidity; guidelines; ventricular dysfunction; HFpEF; HFrEF
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm13072119

Beta blockers (BBs) play a crucial role in enhancing the quality of life and extending the survival of patients with heart failure and reduced ejection fraction (HFrEF). Initiating the therapy at low doses and gradually titrating the dose upwards is recommended to ensure therapeutic efficacy while mitigating potential adverse effects. Vigilant monitoring for signs of drug intolerance is necessary, with dose adjustments as required. The management of older HF patients requires a case-centered approach, taking into account individual comorbidities, functional status, and frailty. Older adults, however, are often underrepresented in randomized clinical trials, leading to some uncertainty in management strategies as patients with HF in clinical practice are older than those enrolled in trials. The present article performs a scoping review of the past 25 years of published literature on BBs in older HF patients, focusing on age, outcomes, and tolerability. Twelve studies (eight randomized-controlled and four observational) encompassing 26,426 patients were reviewed. The results indicate that BBs represent a viable treatment for older HFrEF patients, offering benefits in symptom management, cardiac function, and overall outcomes. Their role in HF with preserved EF, however, remains uncertain. Further research is warranted to refine treatment strategies and address specific aspects in older adults, including proper dosing, therapeutic adherence, and tolerability.